| +0.045 / +1.39%|
The 3 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 1.00. The median estimate represents a +234.86% increase from the last price of 3.29.
The current consensus among 5 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.